Lateral flow technology [1] is used for the detection of proteins, viral antigens and small molecules and enables rapid point-of-care diagnostics of infectious diseases (malaria [2], dengue [3,4], and HIV [5]) as well as cardiac markers (troponin [6]) and cancer biomarkers (prostate specific antigen [7]). The format utilizes a sandwich immunoassay: two antibodies are ultimately bound to an analyte in a sandwich fashion. One antibody (mAb) is initially bound non-covalently in a horizontal stripe on a narrow strip of nitrocellulose. The nitrocellulose is blocked with protein to prevent nonspecific adherence of analyte and other proteins, and the analyte and a second, labeled antibody (typically labeled with colloidal gold) is allowed to flow up the nitrocellulose. A “sandwich” of the analyte and the two antibodies forms on the stripe and appears as a visible, reddish line. Typically, an absorbent pad containing the gold-labeled antibody is used to deliver the reagent, and a control line containing antibody to the Fc portion of the gold-labeled antibody is located upstream of the test line. A diagram of the process is illustrated in Figure 1.